Program
GGTA1 KO Thymokidney
Its studies are mostly in Kidney Failure, Chronic, led by United Therapeutics.
Furthest: phase 2, since Nov 4, 20251 company-led study, 1 open or runningNext primary completion: Nov 2029 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| United Therapeutics | 11 open or running | phase 2since Nov 4, 2025 | Nov 4, 2025 | Nov 2029phase 2 · NCT07224763 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 4, 2025First study: phase 2 study in Renal Insufficiency, ChronicFirst studyNCT07224763 · 50 planned · United States
Ahead
- Nov 2029Primary completion: phase 2 study in Renal Insufficiency, ChronicNCT07224763
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07224763Renal Insufficiency, Chronic · United States | 2 | Recruiting | Nov 2029 | 50 |
How it is read
Names in the registry
- “GGTA1 KO Thymokidney”, 1 entry
Conditions, from the studies’ own filings
- Kidney Failure, Chronic, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.